|Protgen Ltd. Patent applications|
|Patent application number||Title||Published|
|20130243757||METHOD FOR CANCER DETECTION - The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.||09-19-2013|
|20130023479||USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN CANCER PROGNOSIS AND THERAPY - The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.||01-24-2013|
|20120064078||Novel Tumor Biomarket - The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID No.1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.||03-15-2012|
|20100184661||CONJUGATE COMPRISING ANGIOSTATION OR ITS FRAGMENT, THE METHOD FOR PRODUCING THE CONJUGATE AND USE THEREOF - The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as compared to an unmodified angiostatin or its fragments. The modifying agent is selected from the group consisting of macromolecular polymers, protein molecules or fragments thereof, peptides, small molecules, or chemical substances of any other forms.||07-22-2010|
Patent applications by Protgen Ltd.